Stefan M Pfister

List of Publications by Citations

574 papers	57,205 citations	111 h-index	227 g-index
625 ext. papers	73,938 ext. citations	11.3 avg, IF	7.78 L-index

#	Paper	IF	Citations
574	Signatures of mutational processes in human cancer. *Nature*, **2013**, 500, 415-21	50.4	5895
573	Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. *Nature*, **2012**, 482, 226-31	50.4	1655
572	International network of cancer genome projects. *Nature*, **2010**, 464, 993-8	50.4	1613
571	Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. *Cancer Cell*, **2012**, 22, 425-37	24.3	1243
570	Molecular subgroups of medulloblastoma: the current consensus. *Acta Neuropathologica*, **2012**, 123, 465-72	14.3	1167
569	DNA methylation-based classification of central nervous system tumours. *Nature*, **2018**, 555, 469-474	50.4	992
568	Medulloblastoma comprises four distinct molecular variants. *Journal of Clinical Oncology*, **2011**, 29, 1408-14	2.4	919
567	Pan-cancer analysis of whole genomes. *Nature*, **2020**, 578, 82-93	50.4	840
566	Replicative senescence of mesenchymal stem cells: a continuous and organized process. *PLoS ONE*, **2008**, 3, e2213	3.7	795
565	Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. *Acta Neuropathologica*, **2011**, 121, 397-405	14.3	771
564	The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. *Neuro-Oncology* , **2021**, 23, 1231-1251	1	708
563	Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. *Acta Neuropathologica*, **2012**, 123, 473-84	14.3	678
562	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. *Cancer Cell*, **2015**, 27, 728-43	24.3	672
561	K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. *Acta Neuropathologica*, **2012**, 124, 439-47	14.3	629
560	Dissecting the genomic complexity underlying medulloblastoma. *Nature*, **2012**, 488, 100-5	50.4	623
559	The landscape of genomic alterations across childhood cancers. *Nature*, **2018**, 555, 321-327	50.4	603
558	Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. *Cell*, **2012**, 148, 59-71	56.2	600

557	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. *Nature*, **2012**, 488, 49-56	50.4	596
556	Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. *Nature*, **2012**, 488, 106-10	50.4	552
555	Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. *Nature Genetics*, **2013**, 45, 927-32	36.3	550
554	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. *Cell*, **2016**, 164, 1060-1072	36.2	483
553	Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. *Cancer Cell*, **2013**, 24, 660-72	24.3	478
552	The whole-genome landscape of medulloblastoma subtypes. *Nature*, **2017**, 547, 311-317	50.4	472
551	Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. *Cancer Cell*, **2014**, 25, 393-405	24.3	469
550	Medulloblastomics: the end of the beginning. *Nature Reviews Cancer*, **2012**, 12, 818-34	31.3	443
549	Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. *Nature*, **2014**, 506, 445-50	50.4	434
548	Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. *Cancer Cell*, **2017**, 32, 520-537.e5	24.3	423
547	Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. *Cancer Cell*, **2011**, 20, 143-57	24.3	395
546	Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. *Nature Reviews Cancer*, **2014**, 14, 92-107	31.3	383
545	BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. *Journal of Clinical Investigation*, **2008**, 118, 1739-49	15.9	380
544	Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. *Nature*, **2014**, 511, 428-34	50.4	377
543	Glioma. *Nature Reviews Disease Primers*, **2015**, 1, 15017	51.1	368
542	DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. *Lancet Oncology, The*, **2017**, 18, 682-694	21.7	336
541	DNA methylation pattern changes upon long-term culture and aging of human mesenchymal stromal cells. *Aging Cell*, **2010**, 9, 54-63	9.9	325
540	Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. *Acta Neuropathologica*, **2016**, 131, 821-31	14.3	324

539	Clonal selection drives genetic divergence of metastatic medulloblastoma. *Nature*, **2012**, 482, 529-33	50.4	322
538	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. *Cancer Cell*, **2016**, 29, 379-393	24.3	319
537	ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. *Acta Neuropathologica*, **2015**, 129, 133-46	14.3	313
536	Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. *Nature* , **2014**, 510, 537-41	50.4	296
535	Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. *Nature Genetics*, **2014**, 46, 462-6	36.3	296
534	Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. *Acta Neuropathologica*, **2012**, 124, 615-25	14.3	295
533	Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. *Journal of Clinical Oncology*, **2013**, 31, 2927-35	2.2	290
532	Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. *Nature Reviews Genetics*, **2013**, 14, 765-80	30.1	286
531	Challenges to curing primary brain tumours. *Nature Reviews Clinical Oncology*, **2019**, 16, 509-520	19.4	284
530	Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. *Lancet Oncology, The*, **2020**, 21, 531-540	21.7	279
529	BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. *Nature Medicine*, **2013**, 19, 901-908	50.5	279
528	The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. *Cell*, **2013**, 153, 1064-79	56.2	276
527	Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. *Acta Neuropathologica*, **2012**, 123, 615-26	14.3	265
526	Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. *Acta Neuropathologica*, **2013**, 125, 651-8	14.3	247
525	Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. *Clinical Cancer Research*, **2017**, 23, e38-e45	12.9	245
524	Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. *Journal of Clinical Oncology*, **2009**, 27, 1627-36	2.2	238
523	Active medulloblastoma enhancers reveal subgroup-specific cellular origins. *Nature*, **2016**, 530, 57-62	50.4	234
522	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. *Lancet Oncology, The*, **2013**, 14, 1200-7	21.7	226

521	Low physiologic oxygen tensions reduce proliferation and differentiation of human multipotent mesenchymal stromal cells. *BMC Cell Biology*, **2010**, 11, 11		226
520	Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. *Acta Neuropathologica*, **2009**, 118, 401-5	14.3	223
519	Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. *Acta Neuropathologica*, **2015**, 129, 669-78	14.3	220
518	Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking. *Nature Genetics*, **2017**, 49, 65-74	36.3	220
517	The clinical implications of medulloblastoma subgroups. *Nature Reviews Neurology*, **2012**, 8, 340-51	15	217
516	An animal model of MYC-driven medulloblastoma. *Cancer Cell*, **2012**, 21, 155-67	24.3	217
515	Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. *Acta Neuropathologica*, **2013**, 126, 907-15	14.3	211
514	Divergent clonal selection dominates medulloblastoma at recurrence. *Nature*, **2016**, 529, 351-7	50.4	206
513	The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. *Acta Neuropathologica*, **2017**, 133, 5-12	14.3	202
512	Medulloblastoma. *Nature Reviews Disease Primers*, **2019**, 5, 11	51.1	202
511	Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. *Acta Neuropathologica*, **2013**, 125, 659-69	14.3	201
510	Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. *Acta Neuropathologica*, **2014**, 128, 551-9	14.3	200
509	Cytogenetic prognostication within medulloblastoma subgroups. *Journal of Clinical Oncology*, **2014**, 32, 886-96	2.2	199
508	A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. *Nature Communications*, **2015**, 6, 10001	17.4	199
507	Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. *Acta Neuropathologica*, **2015**, 130, 407-17	14.3	194
506	Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. *Acta Neuropathologica*, **2013**, 125, 913-6	14.3	194
505	Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. *Clinical Cancer Research*, **2006**, 12, 2070-9	12.9	193
504	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. *Lancet Oncology, The*, **2016**, 17, 484-495	21.7	187

503	BAF complexes facilitate decatenation of DNA by topoisomerase II. *Nature*, **2013**, 497, 624-7	50.4	187
502	Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study. *European Journal of Cancer*, **2016**, 65, 91-101	7.5	186
501	Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors. *Cancer Cell*, **2015**, 27, 298-311	24.3	183
500	Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. *Lancet Oncology, The*, **2019**, 20, 1011-1022	21.7	182
499	Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling. *Nature Communications*, **2015**, 6, 7391	17.4	181
498	Quiescent sox2(+) cells drive hierarchical growth and relapse in sonic hedgehog subgroup medulloblastoma. *Cancer Cell*, **2014**, 26, 33-47	24.3	181
497	Radiogenomics of Glioblastoma: Machine Learning-based Classification of Molecular Characteristics by Using Multiparametric and Multiregional MR Imaging Features. *Radiology*, **2016**, 281, 907-918	20.5	177
496	Molecular staging of intracranial ependymoma in children and adults. *Journal of Clinical Oncology*, **2010**, 28, 3182-90	2.2	177
495	Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. *Acta Neuropathologica*, **2011**, 121, 763-74	14.3	176
494	Adult medulloblastoma comprises three major molecular variants. *Journal of Clinical Oncology*, **2011**, 29, 2717-23	2.2	176
493	Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. *Lancet Oncology, The*, **2013**, 14, 534-42	21.7	169
492	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. *Acta Neuropathologica*, **2018**, 136, 153-166	14.3	162
491	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. *Lancet Oncology, The*, **2018**, 19, 785-798	21.7	159
490	Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. *Acta Neuropathologica*, **2011**, 122, 231-40	14.3	159
489	Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. *Acta Neuropathologica*, **2013**, 125, 351-8	14.3	158
488	Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. *Acta Neuropathologica*, **2014**, 128, 279-89	14.3	152
487	MAPK pathway activation in pilocytic astrocytoma. *Cellular and Molecular Life Sciences*, **2012**, 69, 1799-811	10.3	152
486	HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth. *Clinical Cancer Research*, **2010**, 16, 3240-52	12.9	152

485	Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. *Acta Neuropathologica*, **2016**, 131, 903-10	14.3	151
484	Molecular neuro-oncology in clinical practice: a new horizon. *Lancet Oncology, The*, **2013**, 14, e370-9	21.7	149
483	Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. *Acta Neuropathologica*, **2014**, 128, 561-71	14.3	148
482	Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. *Acta Neuropathologica*, **2018**, 136, 181-210	14.3	148
481	HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma. *Cancer Cell*, **2016**, 29, 311-323	24.3	146
480	Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. *Neuro-Oncology*, **2014**, 16, 1408-16	1	140
479	Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. *Nature Medicine*, **2016**, 22, 1314-1320	50.5	137
478	Resolving medulloblastoma cellular architecture by single-cell genomics. *Nature*, **2019**, 572, 74-79	50.4	133
477	Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma. *Acta Neuropathologica*, **2012**, 123, 539-52	14.3	132
476	Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management. *Journal of Clinical Oncology*, **2017**, 35, 2370-2377	2.2	129
475	The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma. *International Journal of Cancer*, **2008**, 122, 1207-13	7.5	128
474	Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. *Acta Neuropathologica*, **2013**, 125, 373-84	14.3	126
473	Pediatric high-grade glioma: biologically and clinically in need of new thinking. *Neuro-Oncology*, **2017**, 19, 153-161	1	125
472	FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. *Journal of Clinical Oncology*, **2011**, 29, 3852-61	2.2	125
471	Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. *Journal of Clinical Oncology*, **2018**, 36, 1963-1972	2.2	125
470	Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. *American Journal of Medical Genetics, Part A*, **2017**, 173, 1017-1037	2.5	124
469	Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis. *Lancet Oncology, The*, **2012**, 13, 838-48	21.7	121
468	Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. *Nature*, **2018**, 553, 101-105	50.4	116

467	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. *Acta Neuropathologica*, **2013**, 126, 917-29	14.3	115
466	Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes. *Acta Neuropathologica*, **2010**, 120, 253-60	14.3	115
465	Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. *Acta Neuropathologica*, **2017**, 134, 705-714	14.3	114
464	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. *Journal of Clinical Oncology*, **2016**, 34, 2468-77	2.2	113
463	Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma. *Neuro-Oncology*, **2018**, 20, 848-857	1	111
462	Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. *Acta Neuropathologica*, **2018**, 136, 211-226	14.3	111
461	Methylation-based classification of benign and malignant peripheral nerve sheath tumors. *Acta Neuropathologica*, **2016**, 131, 877-87	14.3	110
460	Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. *Journal of Clinical Oncology*, **2010**, 28, 3054-60	2.2	109
459	Molecular subgroups of medulloblastoma. *Expert Review of Neurotherapeutics*, **2012**, 12, 871-84	4.3	103
458	Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas. *Clinical Cancer Research*, **2011**, 17, 4650-60	12.9	103
457	Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. *Acta Neuropathologica*, **2016**, 131, 137-46	14.3	102
456	Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. *Acta Neuropathologica*, **2018**, 136, 793-803	14.3	102
455	Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles. *Acta Neuropathologica Communications*, **2016**, 4, 20	7.3	101
454	EANO guidelines for the diagnosis and treatment of ependymal tumors. *Neuro-Oncology*, **2018**, 20, 445-456	1	100
453	Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. *Acta Neuropathologica*, **2018**, 136, 273-291	14.3	99
452	Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. *Acta Neuropathologica*, **2014**, 128, 733-41	14.3	96
451	Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. *Lancet Oncology, The*, **2018**, 19, 768-784	21.7	95
450	Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. *Acta Neuropathologica*, **2014**, 128, 137-49	14.3	93

449	cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF mutation. *Acta Neuropathologica*, **2019**, 137, 683-687	14.3	92
448	Novel genomic amplification targeting the microRNA cluster at 19q13.42 in a pediatric embryonal tumor with abundant neuropil and true rosettes. *Acta Neuropathologica*, **2009**, 117, 457-64	14.3	91
447	Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes. *Acta Neuropathologica*, **2019**, 138, 309-326	14.3	90
446	High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response. *Blood*, **2009**, 114, 1053-62	2.2	89
445	Poorly differentiated chordoma with SMARCB1/INI1 loss: a distinct molecular entity with dismal prognosis. *Acta Neuropathologica*, **2016**, 132, 149-51	14.3	89
444	A cell-based model system links chromothripsis with hyperploidy. *Molecular Systems Biology*, **2015**, 11, 828	12.2	88
443	CD28 signaling via VAV/SLP-76 adaptors: regulation of cytokine transcription independent of TCR ligation. *Immunity*, **2001**, 15, 921-33	32.3	88
442	LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). *Acta Neuropathologica*, **2012**, 124, 875-81	14.3	87
441	Nuclear relocation of STAT6 reliably predicts NAB2-STAT6 fusion for the diagnosis of solitary fibrous tumour. *Histopathology*, **2014**, 65, 613-22	7.3	83
440	TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. *Journal of Clinical Oncology*, **2010**, 28, 5188-96	2.2	83
439	The G protein □subunit G□ is a tumor suppressor in Sonic hedgehog-driven medulloblastoma. *Nature Medicine*, **2014**, 20, 1035-42	50.5	82
438	Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial. *Cancer Cell*, **2018**, 33, 829-842.e5	24.3	81
437	Spatial heterogeneity in medulloblastoma. *Nature Genetics*, **2017**, 49, 780-788	36.3	80
436	HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment. *Journal of Neuro-Oncology*, **2012**, 110, 335-48	4.8	80
435	Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma. *Acta Neuropathologica*, **2017**, 133, 431-444	14.3	78
434	GENE-13. PEDIATRIC MENINGIOMAS ARE CHARACTERIZED BY DISTINCT METHYLATION PROFILES DIFFERENT FROM ADULT MENINGIOMAS. *Neuro-Oncology*, **2019**, 21, ii83-ii84	1	78
433	ATRT-09. INTEGRATIVE ANALYSES OF GENE REGULATORY LANDSCAPES REVEAL RHABDOID TUMOR SUBGROUPS WITH POSSIBLE IMMUNE MODULATION THROUGH EPIGENETIC DYSREGULATION. *Neuro-Oncology*, **2019**, 21, ii64-ii65	1	78
432	ATRT-07. TARGETING PRIMARY CILIOGENESIS IN ATYPICAL TERATOID/RHABDOID TUMORS. *Neuro-Oncology*, **2019**, 21, ii64-ii64	1	78

431	EPEN-04. CXorf67 MIMICS ONCOGENIC HISTONE H3 K27M MUTATIONS AND FUNCTIONS AS INTRINSIC INHIBITOR OF PRC2 FUNCTION IN AGGRESSIVE POSTERIOR FOSSA EPENDYMOMA. *Neuro-Oncology*, **2019**, 21, ii78-ii78	1	78
430	GENE-02. CHROMOSOME CONFORMATION ANALYSIS OF EPENDYMOMA IDENTIFIES PUTATIVE TUMOR DEPENDENCY GENES ACTIVATED BY DISTAL ONCOGENIC ENHANCERS. *Neuro-Oncology*, **2019**, 21, ii80-ii81	1	78
429	GENE-04. ESTABLISHING A MOLECULAR PROFILING SERVICE FOR CHILDREN'S CENTRAL NERVOUS SYSTEM TUMORS IN AUSTRALASIA – THE AUSTRALIAN AND NEW ZEALAND CHILDREN'S HAEMATOLOGY AND ONCOLOGY GROUP (ANZCHOG) AIM BRAIN PROJECT. *Neuro-Oncology*, **2019**, 21, ii81-ii81	1	78
428	GENE-06. DISTINCT MOLECULAR SUBGROUPS OF TUMORS OF THE PINEAL REGION CORRELATE WITH CLINICAL PARAMETERS AND GENETIC ALTERATIONS. *Neuro-Oncology*, **2019**, 21, ii81-ii82	1	78
427	LGG-13. PAPILLARY GLIONEURONAL TUMOR (PGNT) EXHIBITS A CHARACTERISTIC METHYLATION PROFILE AND MANDATORY FUSIONS INVOLVING PRKCA. *Neuro-Oncology*, **2019**, 21, ii101-ii102	1	78
426	MEDU-11. MOLECULAR CHARACTERIZATION OF ETMRs REVEALS A ROLE FOR R-LOOP MEDIATED CHROMOSOMAL INSTABILITY. *Neuro-Oncology*, **2019**, 21, ii105-ii105	1	78
425	MPTH-26MOLECULAR REFINEMENT OF PEDIATRIC POSTERIOR FOSSA EPENDYMOMA. *Neuro-Oncology*, **2015**, 17, v144.1-v144	1	78
424	EPIGENOME ALTERATIONS DEFINE LETHAL CIMP POSITIVE EPENDYMOMAS OF INFANCY. *Neuro-Oncology*, **2014**, 16, iii16-iii16	1	78
423	GE-21 * DRASTIC GENOMIC DIVERGENCE OF RECURRENT MEDULLOBLASTOMA INVALIDATES TARGETED THERAPIES DISCOVERED AT DIAGNOSIS. *Neuro-Oncology*, **2014**, 16, v100-v101	1	78
422	EG-09 * EPIGENETIC PROFILING REVEALS A CpG HYPERMETHYLATION PHENOTYPE (CIMP) ASSOCIATED WITH WORSE PROGRESSION-FREE SURVIVAL IN MENINGIOMA. *Neuro-Oncology*, **2014** , 16, v76-v77	1	78
421	EPEN-09. IMPACT OF MOLECULAR SUBGROUP ON OUTCOME FOR INFANTS . *Neuro-Oncology*, **2020** , 22, iii309-iii309	1	78
420	QOL-13. NEUROCOGNITIVE OUTCOMES ACCORDING TO RISK-ADAPTED TREATMENT REGIMENS FOR CHILDREN OLDER THAN 4 WITH MEDULLOBLASTOMA AND POSTERIOR FOSSA EPENDYMOMA – RESULTS OF THE HIT2000 TRIAL. *Neuro-Oncology*, **2020**, 22, iii433-iii433	1	78
419	EPEN-36. THE TREATMENT OUTCOME OF PAEDIATRIC SUPRATENTORIAL C11ORF95-RELA FUSED EPENDYMOMA: A COMBINED REPORT FROM E-HIT SERIES AND AUSTRALIAN NEW ZEALAND CHILDREN'S HAEMATOLOGY/ONCOLOGY GROUP. *Neuro-Oncology*, **2020**, 22, iii315-iii315	1	78
418	MBCL-11. TIME TO RADIOTHERAPY IMPACTS SURVIVAL IN PEDIATRIC AND ADOLESCENT NON-METASTATIC MEDULLOBLASTOMA TREATED BY UPFRONT RADIOTHERAPY – A REPORT FROM THE HIT 2000 TRIAL. *Neuro-Oncology*, **2020**, 22, iii389-iii390	1	78
417	HGG-56. EXTENSIVE MOLECULAR HETEROGENEITY WITHIN H3-/IDH-WILDTYPE PEDIATRIC GLIOBLASTOMA. *Neuro-Oncology*, **2020**, 22, iii354-iii354	1	78
416	ETMR-21. META-ANALYSIS OF PINEAL REGION TUMOURS DEMONSTRATES MOLECULAR SUBGROUPS WITH DISTINCT CLINICO-PATHOLOGICAL FEATURES: A CONSENSUS STUDY. *Neuro-Oncology*, **2020**, 22, iii327-iii327	1	78
415	EPEN-18. CROSS-SPECIES GENOMICS IDENTIFIES GLI2 AS AN ONCOGENE OF C11orf95 FUSION-POSITIVE SUPRATENTORIAL EPENDYMOMA. *Neuro-Oncology*, **2020**, 22, iii311-iii311	1	78
414	EPEN-44. EXTRACELLULAR VESICLES OF SUPRATENTORIAL EPENDYMOMA RELA MEDIATE INTERACTIONS WITH CELLS OF THE TUMOR MICROENVIRONMENT. *Neuro-Oncology*, **2020**, 22, iii316-iii317	1	78

413	MBRS-68. SINGLE NUCLEUS RNA-SEQUENCING DECIPHERS INTRATUMORAL HETEROGENEITY IN MEDULLOBLASTOMA WITH EXTENSIVE NODULARITY (MBEN). *Neuro-Oncology*, **2020**, 22, iii410-iii410	1	78
412	EMBR-01. CLASS I HDAC INHIBITORS AND PLK1 INHIBITORS SYNERGIZE IN MYC-AMPLIFIED MEDULLOBLASTOMA. *Neuro-Oncology*, **2021**, 23, i5-i5	1	78
411	EMBR-21. CLINICALLY TRACTABLE OUTCOME PREDICTION OF GROUP 3/4 MEDULLOBLASTOMA BASED ON TPD52 IMMUNOHISTOCHEMISTRY: A MULTICOHORT STUDY. *Neuro-Oncology*, **2021**, 23, i10-i10	1	78
410	IMMU-14. COMPUTATIONAL DECONVOLUTION OF TUMOR-INFILTRATING IMMUNE COMPONENTS IN PEDIATRIC NERVOUS SYSTEM TUMORS. *Neuro-Oncology*, **2021**, 23, i30-i30	1	78
409	LGG-06. COMPREHENSIVE GENOMIC CHARACTERIZATION AND INTEGRATED CLINICAL ANALYSIS OF LOW-GRADE GLIOMAS IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1. *Neuro-Oncology*, **2021**, 23, i32-i32	1	78
408	EPCT-06. PRECISION ONCOLOGY IN THE PEDIATRIC TARGETED THERAPY 2.0 PROGRAM. *Neuro-Oncology*, **2021**, 23, i47-i48	1	78
407	EPEN-03. ZFTA/C11ORF95 FUSIONS DRIVE SUPRATENTORIAL EPENDYMOMA VIA SHARED ONCOGENIC MECHANISMS. *Neuro-Oncology*, **2021**, 23, i13-i14	1	78
406	LGG-11. BH3-MIMETICS TARGETING BCL-XL SELECTIVELY IMPACT THE SENESCENT COMPARTMENT OF PILOCYTIC ASTROCYTOMA. *Neuro-Oncology*, **2021**, 23, i33-i34	1	78
405	HG-68COMBINED ALTERATIONS IN MAPK PATHWAY GENES, CDKN2A/B AND ATRX CHARACTERIZE ANAPLASTIC PILOCYTIC ASTROCYTOMA. *Neuro-Oncology*, **2016**, 18, iii63.2-iii63	1	78
404	MEDU-21. LOSS OF THE TRANSCRIPTIONAL CO-REPRESSOR BCOR LEADS TO OVEREXPRESSION OF THE GROWTH FACTOR IGF2 AND SHH MEDULLOBLASTOMA TUMOR FORMATION. *Neuro-Oncology*, **2019**, 21, ii107-ii108	1	78
403	Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma. *Nature*, **2019**, 574, 707-711	50.4	78
402	ATRT-24. CHROMATIN SEGMENTATION IN ATRT REVEALS AN IMPORTANT ROLE FOR RESIDUAL SWI/SNF MEMBERS. *Neuro-Oncology*, **2018**, 20, i33-i33	1	78
401	LGG-11. REGULATION OF ONCOGENE-INDUCED SENESCENCE IN PILOCYTIC ASTROCYTOMA. *Neuro-Oncology*, **2018**, 20, i106-i106	1	78
400	MBRS-12. INTERFERENCE WITH THE FUNCTION OF MYC IN GROUP 3 MEDULLOBLASTOMA. *Neuro-Oncology*, **2018**, 20, i130-i130	1	78
399	PDTM-38. PEDIATRIC MENINGIOMAS ARE CHARACTERIZED BY DISTINCT METHYLATION PROFILES DIFFERENT FROM ADULT MENINGIOMAS. *Neuro-Oncology*, **2018**, 20, vi212-vi212	1	78
398	MBCL-45. ROLE OF IRRADIATION IN RELAPSED MEDULLOBLASTOMA: A REPORT OF THE GERMAN MEDULLOBLASTOMA RELAPSE STUDIES. *Neuro-Oncology*, **2018**, 20, i127-i127	1	78
397	EPEN-07. OVEREXPRESSION AND MUTATIONS OF CXORF67 IN INFANT-TYPE POSTERIOR FOSSA TYPE-A (PFA) EPENDYMOMAS. *Neuro-Oncology*, **2018**, 20, i74-i74	1	78
396	ATRT-34. TARGETING PRIMARY CILIOGENESIS IN ATYPICAL TERATOID/RHABDOID TUMORS. *Neuro-Oncology*, **2018**, 20, i35-i35	1	78

395	Recommendations for Cancer Surveillance in Individuals with RASopathies and Other Rare Genetic Conditions with Increased Cancer Risk. *Clinical Cancer Research*, **2017**, 23, e83-e90	12.9	77
394	Pediatric low-grade gliomas: next biologically driven steps. *Neuro-Oncology*, **2018**, 20, 160-173	1	76
393	Chd7 is indispensable for mammalian brain development through activation of a neuronal differentiation programme. *Nature Communications*, **2017**, 8, 14758	17.4	75
392	Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. *Nature Medicine*, **2020**, 26, 712-719	50.5	74
391	Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters. *Journal of Clinical Oncology*, **2016**, 34, 4151-4160	2.2	74
390	Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups. *Cancer Cell*, **2018**, 34, 396-410.e8	24.3	74
389	Sarcoma classification by DNA methylation profiling. *Nature Communications*, **2021**, 12, 498	17.4	74
388	Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma. *International Journal of Cancer*, **2011**, 129, 2297-303	7.5	73
387	Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features. *Acta Neuropathologica*, **2018**, 136, 239-253	14.3	73
386	Molecular diagnostics of CNS embryonal tumors. *Acta Neuropathologica*, **2010**, 120, 553-66	14.3	72
385	Supratentorial primitive neuroectodermal tumors of the central nervous system frequently harbor deletions of the CDKN2A locus and other genomic aberrations distinct from medulloblastomas. *Genes Chromosomes and Cancer*, **2007**, 46, 839-51	5	72
384	A biobank of patient-derived pediatric brain tumor models. *Nature Medicine*, **2018**, 24, 1752-1761	50.5	71
383	H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers. *Acta Neuropathologica*, **2017**, 134, 507-516	14.3	70
382	Differential expression and methylation of brain developmental genes define location-specific subsets of pilocytic astrocytoma. *Acta Neuropathologica*, **2013**, 126, 291-301	14.3	70
381	AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry. *Acta Neuropathologica*, **2013**, 126, 757-62	14.3	69
380	PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. *Cancer Research*, **2017**, 77, e62-e66	10.1	65
379	EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma. *Neuro-Oncology*, **2019**, 21, 878-889	1	65
378	Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis. *Brain Pathology*, **2018**, 28, 656-662	6	65

377	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. *Cancer Discovery*, **2020**, 10, 942-963	24.4	65
376	MLL5 Orchestrates a Cancer Self-Renewal State by Repressing the Histone Variant H3.3 and Globally Reorganizing Chromatin. *Cancer Cell*, **2015**, 28, 715-729	24.3	64
375	MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. *Acta Neuropathologica*, **2012**, 123, 501-13	14.3	64
374	Adaptor FYB (Fyn-binding protein) regulates integrin-mediated adhesion and mediator release: differential involvement of the FYB SH3 domain. *Proceedings of the National Academy of Sciences of the United States of America*, **2001**, 98, 11527-32	11.5	64
373	Molecular characterization of choroid plexus tumors reveals novel clinically relevant subgroups. *Clinical Cancer Research*, **2015**, 21, 184-92	12.9	63
372	Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations. *Acta Neuropathologica*, **2018**, 136, 327-337	14.3	63
371	Real-time PCR assay based on the differential expression of microRNAs and protein-coding genes for molecular classification of formalin-fixed paraffin embedded medulloblastomas. *Neuro-Oncology*, **2013**, 15, 1644-51	1	63
370	A Tumor Suppressor Function for Notch Signaling in Forebrain Tumor Subtypes. *Cancer Cell*, **2015**, 28, 730-742	24.3	63
369	A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat. *Acta Neuropathologica*, **2011**, 122, 637-50	14.3	63
368	Genome-wide molecular characterization of central nervous system primitive neuroectodermal tumor and pineoblastoma. *Neuro-Oncology*, **2011**, 13, 866-79	1	62
367	Aberrant ERBB4-SRC Signaling as a Hallmark of Group 4 Medulloblastoma Revealed by Integrative Phosphoproteomic Profiling. *Cancer Cell*, **2018**, 34, 379-395.e7	24.3	62
366	Sonic hedgehog-associated medulloblastoma arising from the cochlear nuclei of the brainstem. *Acta Neuropathologica*, **2012**, 123, 601-14	14.3	61
365	Role of LIM and SH3 protein 1 (LASP1) in the metastatic dissemination of medulloblastoma. *Cancer Research*, **2010**, 70, 8003-14	10.1	61
364	The RNA-binding protein Musashi1 affects medulloblastoma growth via a network of cancer-related genes and is an indicator of poor prognosis. *American Journal of Pathology*, **2012**, 181, 1762-72	5.8	60
363	Medulloblastomics revisited: biological and clinical insights from thousands of patients. *Nature Reviews Cancer*, **2020**, 20, 42-56	31.3	60
362	Gliomatosis cerebri: no evidence for a separate brain tumor entity. *Acta Neuropathologica*, **2016**, 131, 309-319	14.3	59
361	Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. *Neuro-Oncology*, **2014**, 16, 1630-8	1	59
360	Array-based DNA-methylation profiling in sarcomas with small blue round cell histology provides valuable diagnostic information. *Modern Pathology*, **2018**, 31, 1246-1256	9.8	58

359	Medulloblastoma subgroups remain stable across primary and metastatic compartments. *Acta Neuropathologica*, **2015**, 129, 449-57	14.3	58
358	Coverage bias and sensitivity of variant calling for four whole-genome sequencing technologies. *PLoS ONE*, **2013**, 8, e66621	3.7	58
357	The genetics of pediatric brain tumors. *Current Neurology and Neuroscience Reports*, **2010**, 10, 215-23	6.6	58
356	Mechismo: predicting the mechanistic impact of mutations and modifications on molecular interactions. *Nucleic Acids Research*, **2015**, 43, e10	20.1	57
355	Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. *Acta Neuropathologica*, **2012**, 123, 515-27	14.3	57
354	MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma. *Acta Neuropathologica*, **2012**, 123, 529-38	14.3	56
353	Evidence of H3 K27M mutations in posterior fossa ependymomas. *Acta Neuropathologica*, **2016**, 132, 635-7	14.3	55
352	Secretion of angiogenic proteins by human multipotent mesenchymal stromal cells and their clinical potential in the treatment of avascular osteonecrosis. *Leukemia*, **2008**, 22, 2054-61	10.7	55
351	N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. *Neuro-Oncology*, **2019**, 21, 95-105	1	55
350	Melanotic tumors of the nervous system are characterized by distinct mutational, chromosomal and epigenomic profiles. *Brain Pathology*, **2015**, 25, 202-8	6	54
349	Array-based profiling of reference-independent methylation status (aPRIMES) identifies frequent promoter methylation and consecutive downregulation of ZIC2 in pediatric medulloblastoma. *Nucleic Acids Research*, **2007**, 35, e51	20.1	54
348	An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice. *Journal of Clinical Investigation*, **2011**, 121, 1344-8	15.9	54
347	Next-generation (epi)genetic drivers of childhood brain tumours and the outlook for targeted therapies. *Lancet Oncology, The*, **2015**, 16, e293-302	21.7	53
346	Heterogeneity within the PF-EPN-B ependymoma subgroup. *Acta Neuropathologica*, **2018**, 136, 227-237	14.3	52
345	Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours. *Nature Reviews Cancer*, **2019**, 19, 420-438	31.3	52
344	Integrative Genome-Scale Analysis Identifies Epigenetic Mechanisms of Transcriptional Deregulation in Unfavorable Neuroblastomas. *Cancer Research*, **2016**, 76, 5523-37	10.1	52
343	MYCN amplification drives an aggressive form of spinal ependymoma. *Acta Neuropathologica*, **2019**, 138, 1075-1089	14.3	51
342	Recurrent intragenic rearrangements of EGFR and BRAF in soft tissue tumors of infants. *Nature Communications*, **2018**, 9, 2378	17.4	50

341	Hypermutation of the inactive X chromosome is a frequent event in cancer. *Cell*, **2013**, 155, 567-81	56.2	50
340	Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective. *Nature Reviews Clinical Oncology*, **2017**, 14, 497-507	19.4	49
339	Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre. *Acta Neuropathologica Communications*, **2019**, 7, 24	7.3	49
338	Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location. *Acta Neuropathologica Communications*, **2018**, 6, 117	7.3	48
337	Germline Elongator mutations in Sonic Hedgehog medulloblastoma. *Nature*, **2020**, 580, 396-401	50.4	47
336	Pediatric low-grade gliomas: implications of the biologic era. *Neuro-Oncology*, **2017**, 19, 750-761	1	47
335	Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma. *Acta Neuropathologica Communications*, **2015**, 3, 22	7.3	46
334	Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma. *Cancer Research*, **2015**, 75, 134-46	10.1	46
333	Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups. *Neuro-Oncology*, **2016**, 18, 790-6	1	46
332	Genomic and transcriptomic analyses match medulloblastoma mouse models to their human counterparts. *Acta Neuropathologica*, **2014**, 128, 123-36	14.3	46
331	Histology and molecular pathology of pediatric brain tumors. *Journal of Child Neurology*, **2009**, 24, 1375-86	2.5	46
330	The molecular landscape of ETMR at diagnosis and relapse. *Nature*, **2019**, 576, 274-280	50.4	46
329	Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial. *Annals of Oncology*, **2018**, 29, 1423-1430	10.3	45
328	Medulloblastoma-associated DDX3 variant selectively alters the translational response to stress. *Oncotarget*, **2016**, 7, 28169-82	3.3	44
327	FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma. *EMBO Journal*, **2016**, 35, 2192-2212	13	44
326	Molecular mechanisms and therapeutic targets in pediatric brain tumors. *Science Signaling*, **2017**, 10,	8.8	43
325	Implementation of mechanism of action biology-driven early drug development for children with cancer. *European Journal of Cancer*, **2016**, 62, 124-31	7.5	43
324	Integrated molecular characterization of IDH-mutant glioblastomas. *Neuropathology and Applied Neurobiology*, **2019**, 45, 108-118	5.2	42

323	Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain. *Acta Neuropathologica*, **2015**, 130, 419-34	14.3	41
322	Overcoming multiple drug resistance mechanisms in medulloblastoma. *Acta Neuropathologica Communications*, **2014**, 2, 57	7.3	41
321	Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors with Cytotoxic T Cell Infiltration. *Cell Reports*, **2019**, 29, 2338-2354.e7	10.6	40
320	Single-Cell RNA-Seq Reveals Cellular Hierarchies and Impaired Developmental Trajectories in Pediatric Ependymoma. *Cancer Cell*, **2020**, 38, 44-59.e9	24.3	40
319	Comprehensive Analysis of Chromatin States in Atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and Polycomb in Gene Regulation. *Cancer Cell*, **2019**, 35, 95-110.e8	24.3	40
318	YAP1 subgroup supratentorial ependymoma requires TEAD and nuclear factor I-mediated transcriptional programmes for tumorigenesis. *Nature Communications*, **2019**, 10, 3914	17.4	39
317	Subgroup-specific localization of human medulloblastoma based on pre-operative MRI. *Acta Neuropathologica*, **2014**, 127, 931-3	14.3	39
316	Moyamoya-like vasculopathy (moyamoya syndrome) in children. *Childs Nervous System*, **2004**, 20, 382-91	1.7	39
315	Defective DNA damage repair leads to frequent catastrophic genomic events in murine and human tumors. *Nature Communications*, **2018**, 9, 4760	17.4	37
314	Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1. *Acta Neuropathologica*, **2019**, 138, 497-504	14.3	36
313	Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). *Neuro-Oncology*, **2018**, 20, 400-410	1	36
312	cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification. *Brain Pathology*, **2017**, 27, 851-852	6	36
311	Transitioning from genotypes to epigenotypes: why the time has come for medulloblastoma epigenomics. *Neuroscience*, **2014**, 264, 171-85	3.9	36
310	Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype. *Clinical Cancer Research*, **2015**, 21, 3750-8	12.9	35
309	DNA methylation-based reclassification of olfactory neuroblastoma. *Acta Neuropathologica*, **2018**, 136, 255-271	14.3	35
308	Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation. *Neuro-Oncology*, **2018**, 20, 367-379	1	35
307	The Shh receptor Boc promotes progression of early medulloblastoma to advanced tumors. *Developmental Cell*, **2014**, 31, 34-47	10.2	35
306	From class waivers to precision medicine in paediatric oncology. *Lancet Oncology, The*, **2017**, 18, e394-e404	24.7	35

305	Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course. *Acta Neuropathologica*, **2020**, 139, 193-209	14.3	35
304	Itch/β-arrestin2-dependent non-proteolytic ubiquitylation of SuFu controls Hedgehog signalling and medulloblastoma tumorigenesis. *Nature Communications*, **2018**, 9, 976	17.4	34
303	Cribriform neuroepithelial tumor: molecular characterization of a SMARCB1-deficient non-rhabdoid tumor with favorable long-term outcome. *Brain Pathology*, **2017**, 27, 411-418	6	34
302	The WIP1 oncogene promotes progression and invasion of aggressive medulloblastoma variants. *Oncogene*, **2015**, 34, 1126-40	9.2	34
301	Nestin expression identifies ependymoma patients with poor outcome. *Brain Pathology*, **2012**, 22, 848-60	6	34
300	Hedgehog-mediated regulation of PPARδ controls metabolic patterns in neural precursors and shh-driven medulloblastoma. *Acta Neuropathologica*, **2012**, 123, 587-600	14.3	34
299	Machine learning workflows to estimate class probabilities for precision cancer diagnostics on DNA methylation microarray data. *Nature Protocols*, **2020**, 15, 479-512	18.8	34
298	Telomere dysfunction and chromothripsis. *International Journal of Cancer*, **2016**, 138, 2905-14	7.5	34
297	Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children's Oncology Group Randomized ACNS0332 Trial. *Journal of Clinical Oncology*, **2018**, JCO2017764720	2.2	34
296	Molecular stratification of medulloblastoma: comparison of histological and genetic methods to detect Wnt activated tumours. *Neuropathology and Applied Neurobiology*, **2015**, 41, 135-44	5.2	33
295	Histone H3 wild-type DIPG/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation. *Acta Neuropathologica*, **2020**, 139, 1109-1113	14.3	33
294	DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment. *Neuro-Oncology*, **2018**, 20, 1616-1624	1	32
293	WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. *Acta Neuropathologica Communications*, **2014**, 2, 174	7.3	32
292	No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3. *Klinische Padiatrie*, **2016**, 228, 113-7	0.9	32
291	Engineering Genetic Predisposition in Human Neuroepithelial Stem Cells Recapitulates Medulloblastoma Tumorigenesis. *Cell Stem Cell*, **2019**, 25, 433-446.e7	18	31
290	Recurrent homozygous deletion of DROSHA and microduplication of PDE4DIP in pineoblastoma. *Nature Communications*, **2018**, 9, 2868	17.4	31
289	The role of chromatin remodeling in medulloblastoma. *Brain Pathology*, **2013**, 23, 193-9	6	31
288	EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. *Lancet Oncology, The*, **2019**, 20, e715-e728	21.7	31

287	Lsd1 as a therapeutic target in Gfi1-activated medulloblastoma. *Nature Communications*, **2019**, 10, 332	17.4	30
286	Loss of Smarc proteins impairs cerebellar development. *Journal of Neuroscience*, **2014**, 34, 13486-91	6.6	30
285	Histone 3.3 hotspot mutations in conventional osteosarcomas: a comprehensive clinical and molecular characterization of six H3F3A mutated cases. *Clinical Sarcoma Research*, **2017**, 7, 9	2.5	30
284	Pediatric gliomas. *Recent Results in Cancer Research*, **2009**, 171, 67-81	1.5	30
283	Diagnostics of pediatric supratentorial RELA ependymomas: integration of information from histopathology, genetics, DNA methylation and imaging. *Brain Pathology*, **2019**, 29, 325-335	6	30
282	Genomic profiling of Acute lymphoblastic leukemia in ataxia telangiectasia patients reveals tight link between ATM mutations and chromothripsis. *Leukemia*, **2017**, 31, 2048-2056	10.7	29
281	Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells. *Oncogene*, **2017**, 36, 5231-5242	9.2	29
280	DNA methylation profiling distinguishes Ewing-like sarcoma with EWSR1-NFATc2 fusion from Ewing sarcoma. *Journal of Cancer Research and Clinical Oncology*, **2019**, 145, 1273-1281	4.9	29
279	Sellar Region Atypical Teratoid/Rhabdoid Tumors (ATRT) in Adults Display DNA Methylation Profiles of the ATRT-MYC Subgroup. *American Journal of Surgical Pathology*, **2018**, 42, 506-511	6.7	29
278	Comparative integrated molecular analysis of intraocular medulloepitheliomas and central nervous system embryonal tumors with multilayered rosettes confirms that they are distinct nosologic entities. *Neuropathology*, **2015**, 35, 538-44	2	29
277	Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. *Cell*, **2020**, 183, 1617-1633.e22	56.2	29
276	Somatic mutations of DICER1 and KMT2D are frequent in intraocular medulloepitheliomas. *Genes Chromosomes and Cancer*, **2016**, 55, 418-27	5	29
275	FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytoma. *Acta Neuropathologica*, **2018**, 136, 293-302	14.3	29
274	Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience. *European Journal of Cancer*, **2019**, 114, 27-35	7.5	28
273	Tissue Factor Regulation by miR-520g in Primitive Neuronal Brain Tumor Cells: A Possible Link between Oncomirs and the Vascular Tumor Microenvironment. *American Journal of Pathology*, **2016**, 186, 446-59	5.8	28
272	Whole exome sequencing reveals that the majority of schwannomatosis cases remain unexplained after excluding SMARCB1 and LZTR1 germline variants. *Acta Neuropathologica*, **2014**, 128, 449-52	14.3	28
271	The transcription factor evi-1 is overexpressed, promotes proliferation, and is prognostically unfavorable in infratentorial ependymomas. *Clinical Cancer Research*, **2011**, 17, 3631-7	12.9	28
270	Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing. *Oncotarget*, **2017**, 8, 11460-11479	3.3	28

269	Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCA. *Acta Neuropathologica*, **2019**, 137, 837-846	14.3	28
268	Germline Mutations Predispose to Pediatric Medulloblastoma. *Journal of Clinical Oncology*, **2020**, 38, 43-50	2.2	28
267	Mutational patterns and regulatory networks in epigenetic subgroups of meningioma. *Acta Neuropathologica*, **2019**, 138, 295-308	14.3	27
266	Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot study. *Neuro-Oncology*, **2018**, 20, 826-837	1	27
265	CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. *Acta Neuropathologica*, **2020**, 140, 409-413	14.3	26
264	Identification of genes involved in the biology of atypical teratoid/rhabdoid tumours using Drosophila melanogaster. *Nature Communications*, **2014**, 5, 4005	17.4	26
263	Preliminary experience with personalized and targeted therapy for pediatric brain tumors. *Pediatric Blood and Cancer*, **2012**, 59, 27-33	3	26
262	Critical role of zinc finger protein 521 in the control of growth, clonogenicity and tumorigenic potential of medulloblastoma cells. *Oncotarget*, **2013**, 4, 1280-92	3.3	26
261	The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma. *Clinical Cancer Research*, **2019**, 25, 1851-1866	12.9	26
260	Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients. *Neuro-Oncology*, **2017**, 19, 1607-1617	1	25
259	Genome-wide methylation profiling and copy number analysis in atypical fibroxanthomas and pleomorphic dermal sarcomas indicate a similar molecular phenotype. *Clinical Sarcoma Research*, **2019**, 9, 2	2.5	25
258	Opposing Effects of CREBBP Mutations Govern the Phenotype of Rubinstein-Taybi Syndrome and Adult SHH Medulloblastoma. *Developmental Cell*, **2018**, 44, 709-724.e6	10.2	25
257	Arhgap36-dependent activation of Gli transcription factors. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 11061-6	11.5	25
256	The □catenin/CBP-antagonist ICG-001 inhibits pediatric glioma tumorigenicity in a Wnt-independent manner. *Oncotarget*, **2017**, 8, 27300-27313	3.3	25
255	Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). *Journal of Clinical Oncology*, **2021**, 39, 822-835	2.2	25
254	Papillary Tumor of the Pineal Region: A Distinct Molecular Entity. *Brain Pathology*, **2016**, 26, 199-205	6	25
253	Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain. *Neuro-Oncology*, **2017**, 19, 1183-1194	1	24
252	TelomereHunter - in silico estimation of telomere content and composition from cancer genomes. *BMC Bioinformatics*, **2019**, 20, 272	3.6	24

251	EGFL7 enhances surface expression of integrin β3 to promote angiogenesis in malignant brain tumors. *EMBO Molecular Medicine*, **2018**, 10,	12	24
250	Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma. *Neuro-Oncology*, **2018**, 20, 1517-1524	1	24
249	Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions. *Acta Neuropathologica*, **2019**, 138, 827-835	14.3	24
248	Neogenin1 is a Sonic Hedgehog target in medulloblastoma and is necessary for cell cycle progression. *International Journal of Cancer*, **2014**, 134, 21-31	7.5	24
247	YAP1-fusions in pediatric NF2-wildtype meningioma. *Acta Neuropathologica*, **2020**, 139, 215-218	14.3	24
246	Primary intracranial sarcomas with DICER1 mutation often contain prominent eosinophilic cytoplasmic globules and can occur in the setting of neurofibromatosis type 1. *Acta Neuropathologica*, **2019**, 137, 521-525	14.3	24
245	Intraocular Medulloepitheliomas and Embryonal Tumors With Multilayered Rosettes of the Brain: Comparative Roles of LIN28A and C19MC. *American Journal of Ophthalmology*, **2015**, 159, 1065-1074.e1	4.9	23
244	Coagulation and angiogenic gene expression profiles are defined by molecular subgroups of medulloblastoma: evidence for growth factor-thrombin cross-talk. *Journal of Thrombosis and Haemostasis*, **2014**, 12, 1838-49	15.4	23
243	Subgroup-specific alternative splicing in medulloblastoma. *Acta Neuropathologica*, **2012**, 123, 485-499	14.3	23
242	Key Implications of Data Sharing in Pediatric Genomics. *JAMA Pediatrics*, **2018**, 172, 476-481	8.3	22
241	PID1 (NYGGF4), a new growth-inhibitory gene in embryonal brain tumors and gliomas. *Clinical Cancer Research*, **2014**, 20, 827-36	12.9	22
240	Update on molecular and genetic alterations in adult medulloblastoma. *Memo - Magazine of European Medical Oncology*, **2012**, 5, 228-232	0.3	22
239	Stepwise accumulation of distinct genomic aberrations in a patient with progressively metastasizing ependymoma. *Genes Chromosomes and Cancer*, **2009**, 48, 229-38	5	22
238	Accumulation of genomic aberrations during clinical progression of medulloblastoma. *Acta Neuropathologica*, **2008**, 116, 383-90	14.3	22
237	Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma. *Oncotarget*, **2016**, 7, 61860-61873	3.3	22
236	Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma. *Journal of Neuro-Oncology*, **2016**, 129, 109-21	4.8	22
235	Nestin Mediates Hedgehog Pathway Tumorigenesis. *Cancer Research*, **2016**, 76, 5573-83	10.1	22
234	A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR. *Neuro-Oncology*, **2021**, 23, 34-43	1	22

233	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. *Cancer Discovery*, **2021**, 11, 2764-2779	24.4	22
232	Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. *Neuro-Oncology*, **2020**, 22, 773-784	1	21
231	Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort. *Journal of Clinical Oncology*, **2020**, 38, 2028-2040	2.2	21
230	Proteomic analysis of Medulloblastoma reveals functional biology with translational potential. *Acta Neuropathologica Communications*, **2018**, 6, 48	7.3	21
229	DNA methylation-based profiling for paediatric CNS tumour diagnosis and treatment: a population-based study. *The Lancet Child and Adolescent Health*, **2020**, 4, 121-130	14.5	21
228	No correlation between NF1 mutation position and risk of optic pathway glioma in 77 unrelated NF1 patients. *Human Genetics*, **2016**, 135, 469-475	6.3	21
227	DNA-methylation profiling discloses significant advantages over NanoString method for molecular classification of medulloblastoma. *Acta Neuropathologica*, **2017**, 134, 965-967	14.3	20
226	ETMR: a tumor entity in its infancy. *Acta Neuropathologica*, **2020**, 140, 249-266	14.3	20
225	Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations. *Acta Neuropathologica*, **2020**, 139, 243-257	14.3	20
224	Response to trametinib treatment in progressive pediatric low-grade glioma patients. *Journal of Neuro-Oncology*, **2020**, 149, 499-510	4.8	20
223	Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion-Positive Supratentorial Ependymomas. *Cancer Discovery*, **2021**, 11, 2230-2247	24.4	20
222	Meningiomas induced by low-dose radiation carry structural variants of NF2 and a distinct mutational signature. *Acta Neuropathologica*, **2017**, 134, 155-158	14.3	19
221	Embryonal tumor with abundant neuropil and true rosettes (ETANTR) with loss of morphological but retained genetic key features during progression. *Acta Neuropathologica*, **2011**, 122, 787-90	14.3	19
220	Molecular approaches to ependymoma: the next step(s). *Current Opinion in Neurology*, **2012**, 25, 745-50	7.1	19
219	DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics. *Journal of Cancer Research and Clinical Oncology*, **2020**, 146, 97-104	4.9	19
218	Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. *Acta Neuropathologica Communications*, **2019**, 7, 163	7.3	18
217	Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. *Nature Communications*, **2019**, 10, 2400	17.4	18
216	Emerging insights into the ependymoma epigenome. *Brain Pathology*, **2013**, 23, 206-9	6	18

215	Epidemiology, molecular classification and WHO grading of ependymoma. *Journal of Neurosurgical Sciences*, **2018**, 62, 46-50	1.3	18
214	Serpine2/PN-1 Is Required for Proliferative Expansion of Pre-Neoplastic Lesions and Malignant Progression to Medulloblastoma. *PLoS ONE*, **2015**, 10, e0124870	3.7	18
213	PCDH10 is a candidate tumour suppressor gene in medulloblastoma. *Childs Nervous System*, **2011**, 27, 1243-9	1.7	18
212	RF_Purify: a novel tool for comprehensive analysis of tumor-purity in methylation array data based on random forest regression. *BMC Bioinformatics*, **2019**, 20, 428	3.6	17
211	Fatal Outcome of European Tick-borne Encephalitis after Vaccine Failure. *Frontiers in Neurology*, **2017**, 8, 119	4.1	17
210	Proteomic profiling of high risk medulloblastoma reveals functional biology. *Oncotarget*, **2015**, 6, 14584-95	3.3	17
209	Infratentorial IDH-mutant astrocytoma is a distinct subtype. *Acta Neuropathologica*, **2020**, 140, 569-581	14.3	17
208	Duplications of KIAA1549 and BRAF screening by Droplet Digital PCR from formalin-fixed paraffin-embedded DNA is an accurate alternative for KIAA1549-BRAF fusion detection in pilocytic astrocytomas. *Modern Pathology*, **2018**, 31, 1490-1501	9.8	17
207	DECIPHER pooled shRNA library screen identifies PP2A and FGFR signaling as potential therapeutic targets for diffuse intrinsic pontine gliomas. *Neuro-Oncology*, **2019**, 21, 867-877	1	16
206	Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation. *Acta Neuropathologica*, **2018**, 135, 635-638	14.3	16
205	p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas. *Human Molecular Genetics*, **2014**, 23, 6826-37	5.6	16
204	Oncolytic effects of parvovirus H-1 in medulloblastoma are associated with repression of master regulators of early neurogenesis. *International Journal of Cancer*, **2014**, 134, 703-16	7.5	16
203	An essential role for p38 MAPK in cerebellar granule neuron precursor proliferation. *Acta Neuropathologica*, **2012**, 123, 573-86	14.3	16
202	ZFTA-RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial Ependymoma. *Cancer Discovery*, **2021**, 11, 2200-2215	24.4	16
201	A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma. *Clinical Cancer Research*, **2018**, 24, 1355-1363	12.9	15
200	Myxoid glioneuronal tumor of the septum pellucidum and lateral ventricle is defined by a recurrent PDGFRA p.K385 mutation and DNT-like methylation profile. *Acta Neuropathologica*, **2018**, 136, 339-343	14.3	15
199	Epigenetic Silencing of DKK3 in medulloblastoma. *International Journal of Molecular Sciences*, **2013**, 14, 7492-505	6.3	15
198	Diffuse glioneuronal tumour with oligodendroglioma-like features and nuclear clusters (DGONC) - a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14. *Neuropathology and Applied Neurobiology*, **2020**, 46, 422-430	5.2	15

197	Super enhancers define regulatory subtypes and cell identity in neuroblastoma.. *Nature Cancer*, **2021**, 2, 114-128	15.4	15
196	Prognostic relevance of miR-124-3p and its target TP53INP1 in pediatric ependymoma. *Genes Chromosomes and Cancer*, **2017**, 56, 639-650	5	14
195	Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib. *Pediatric Blood and Cancer*, **2018**, 65, e26893	3	14
194	Molecular dissection of ependymomas. *Oncoscience*, **2015**, 2, 827-8	0.8	14
193	Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. *Acta Neuropathologica*, **2021**, 141, 85-100	14.3	14
192	Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. *Neuro-Oncology*, **2021**, 23, 1360-1370	1	14
191	Translocations Constitute Ependymoma Chromatin Remodeling and Transcription Factors. *Cancer Discovery*, **2021**, 11, 2216-2229	24.4	13
190	H3.3-K27M drives neural stem cell-specific gliomagenesis in a human iPSC-derived model. *Cancer Cell*, **2021**, 39, 407-422.e13	24.3	13
189	DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomas. *Neuro-Oncology*, **2019**, 21, 214-221	1	13
188	BRAF V600E Status Alone Is Not Sufficient as a Prognostic Biomarker in Pediatric Low-Grade Glioma. *Journal of Clinical Oncology*, **2018**, 36, 96	2.2	13
187	Infection as a cause of childhood leukemia: virus detection employing whole genome sequencing. *Haematologica*, **2017**, 102, e179-e183	6.6	12
186	Long-term survival in a case of ETANTR with histological features of neuronal maturation after therapy. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2015**, 466, 603-7	5.1	12
185	DNA copy number alterations in central primitive neuroectodermal tumors and tumors of the pineal region: an international individual patient data meta-analysis. *Journal of Neuro-Oncology*, **2012**, 109, 415-23	4.8	12
184	Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome. *Nature Communications*, **2021**, 12, 1269	17.4	12
183	INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies. *BMC Cancer*, **2020**, 20, 523	4.8	11
182	Rapid and Sensitive Drug Quantification in Tissue Sections Using Matrix Assisted Laser Desorption Ionization-Ion Mobility-Mass Spectrometry Profiling. *Journal of the American Society for Mass Spectrometry*, **2020**, 31, 742-751	3.5	11
181	Opposing Tumor-Promoting and -Suppressive Functions of Rictor/mTORC2 Signaling in Adult Glioma and Pediatric SHH Medulloblastoma. *Cell Reports*, **2018**, 24, 463-478.e5	10.6	11
180	TelomereHunter: telomere content estimation and characterization from whole genome sequencing data		11

179	SHH desmoplastic/nodular medulloblastoma and Gorlin syndrome in the setting of Down syndrome: case report, molecular profiling, and review of the literature. *Childks Nervous System*, **2016**, 32, 2439-2446	1.7	11
178	Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas. *Acta Neuropathologica*, **2017**, 133, 325-327	14.3	10
177	Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification. *PLoS ONE*, **2017**, 12, e0178351	3.7	10
176	Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group. *Lancet Oncology, The*, **2018**, 19, e419-e428	21.7	10
175	Sorafenib plus valproic acid for infant spinal glioblastoma. *Journal of Pediatric Hematology/Oncology*, **2010**, 32, 511-4	1.2	10
174	Non-random aneuploidy specifies subgroups of pilocytic astrocytoma and correlates with older age. *Oncotarget*, **2015**, 6, 31844-56	3.3	10
173	Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study. *Neuro-Oncology*, **2021**, 23, 1012-1023	1	10
172	Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors. *Brain Pathology*, **2016**, 26, 506-16	6	10
171	Receptor activator of nuclear factor kappaB ligand plays a nonredundant role in doxorubicin-induced apoptosis. *Cancer Research*, **2003**, 63, 1772-5	10.1	10
170	Molecular characterization of medulloblastomas with extensive nodularity (MBEN). *Acta Neuropathologica*, **2018**, 136, 303-313	14.3	9
169	The pediatric precision oncology study INFORM: Clinical outcome and benefit for molecular subgroups.. *Journal of Clinical Oncology*, **2020**, 38, LBA10503-LBA10503	2.2	9
168	Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1. *Acta Neuropathologica*, **2021**, 141, 281-290	14.3	9
167	Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma. *Cancer Research*, **2020**, 80, 5393-5407	10.1	9
166	Functional loss of a noncanonical BCOR-PRC1.1 complex accelerates SHH-driven medulloblastoma formation. *Genes and Development*, **2020**, 34, 1161-1176	12.6	9
165	DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival. *Neuro-Oncology*, **2021**, 23, 240-250	1	9
164	Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study. *Acta Neuropathologica*, **2021**, 141, 771-785	14.3	9
163	Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1). *Acta Neuropathologica*, **2021**, 141, 605-617	14.3	9
162	Molecular correlates of cerebellar mutism syndrome in medulloblastoma. *Neuro-Oncology*, **2020**, 22, 290-297	1	8

161	InTAD: chromosome conformation guided analysis of enhancer target genes. *BMC Bioinformatics*, **2019**, 20, 60	3.6	8
160	Translating genomic medicine to the clinic: challenges and opportunities. *Genome Medicine*, **2019**, 11, 9	14.4	8
159	Performance of HBsAg point-of-care tests for detection of diagnostic escape-variants in clinical samples. *Journal of Clinical Virology*, **2015**, 69, 33-5	14.5	8
158	Connect four with glioblastoma stem cell factors. *Cell*, **2014**, 157, 525-7	56.2	8
157	Absence of chromosome 19q13.41 amplification in a case of atypical teratoid/rhabdoid tumor with ependymoblastic differentiation. *Acta Neuropathologica*, **2011**, 121, 283-5	14.3	8
156	Novel oncogene amplifications in tumors from a family with Li-Fraumeni syndrome. *Genes Chromosomes and Cancer*, **2009**, 48, 558-68	5	8
155	Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. *Journal of Clinical Oncology*, **2021**, 39, 3839-3852	2.2	8
154	Rapid and Sensitive Quantification of Osimertinib in Human Plasma Using a Fully Validated MALDI-IM-MS/MS Assay. *Cancers*, **2020**, 12,	6.6	8
153	Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia. *Clinical Epigenetics*, **2019**, 11, 188	7.7	8
152	Developmental and evolutionary dynamics of cis-regulatory elements in mouse cerebellar cells. *Science*, **2021**, 373,	33.3	8
151	SMAD dependent signaling plays a detrimental role in a fly model of SMARCB1-deficiency and the biology of atypical teratoid/rhabdoid tumors. *Journal of Neuro-Oncology*, **2017**, 131, 477-484	4.8	7
150	Systematic identification of suspected anthelmintic benzimidazole metabolites using LC-MS/MS. *Journal of Pharmaceutical and Biomedical Analysis*, **2018**, 151, 151-158	3.5	7
149	Simple estimation of incident HIV infection rates in notification cohorts based on window periods of algorithms for evaluation of line-immunoassay result patterns. *PLoS ONE*, **2013**, 8, e71662	3.7	7
148	From glioblastoma to gangliocytoma: an unforeseen but welcome shift in biological behavior. *Journal of Neurosurgery: Pediatrics*, **2009**, 4, 475-8	2.1	7
147	Second series by the Italian Association of Pediatric Hematology and Oncology of children and adolescents with intracranial ependymoma: an integrated molecular and clinical characterization with a long-term follow-up. *Neuro-Oncology*, **2021**, 23, 848-857	1	7
146	Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma. *Science Translational Medicine*, **2021**, 13,	17.5	7
145	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. *Journal of Clinical Oncology*, **2021**, 39, 807-821	2.2	7
144	PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum. *Acta Neuropathologica*, **2021**, 142, 841-857	14.3	7

143	MEK and RAF inhibitors: time for a paradigm shift in the treatment of pediatric low-grade gliomas?. *Neuro-Oncology*, **2017**, 19, 741-743	1	6
142	Evaluation of Prognostic Factors and Role of Participation in a Randomized Trial or a Prospective Registry in Pediatric and Adolescent Nonmetastatic Medulloblastoma - A Report From the HIT 2000 Trial. *Advances in Radiation Oncology*, **2020**, 5, 1158-1169	3.3	6
141	TP53 codon 72 polymorphism may predict early tumour progression in paediatric pilocytic astrocytoma. *Oncotarget*, **2016**, 7, 47918-47926	3.3	6
140	Limitations of current models for testing the clinical potential of epigenetic inhibitors for treatment of pediatric ependymoma. *Oncotarget*, **2018**, 9, 36530-36541	3.3	6
139	Posterior fossa pilocytic astrocytomas with oligodendroglial features show frequent FGFR1 activation via fusion or mutation. *Acta Neuropathologica*, **2020**, 139, 403-406	14.3	6
138	EORTC SPECTA-AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe. *International Journal of Cancer*, **2020**, 147, 1180-1184	7.5	6
137	Transcriptional profiling of medulloblastoma with extensive nodularity (MBEN) reveals two clinically relevant tumor subsets with VSNL1 as potent prognostic marker. *Acta Neuropathologica*, **2020**, 139, 583-596	14.3	6
136	Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series. *Oncologist*, **2019**, 24, e921-e929	5.7	6
135	MRI Features of Histologically Diagnosed Supratentorial Primitive Neuroectodermal Tumors and Pineoblastomas in Correlation with Molecular Diagnoses and Outcomes: A Report from the Children's Oncology Group ACNS0332 Trial. *American Journal of Neuroradiology*, **2019**, 40, 1796-1803	4.4	6
134	Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma. *Neuro-Oncology*, **2021**, 23, 226-239	1	6
133	Imaging Characteristics of Wingless Pathway Subgroup Medulloblastomas: Results from the German HIT/SIOP-Trial Cohort. *American Journal of Neuroradiology*, **2019**, 40, 1811-1817	4.4	5
132	A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in -Driven Pediatric Low-Grade Glioma Cells. *Molecular Cancer Therapeutics*, **2020**, 19, 1736-1750	6.1	5
131	Abstract 4347: Medulloblastoma comprises four distinct diseases **2010**,		5
130	Drivers underpinning the malignant transformation of giant cell tumour of bone. *Journal of Pathology*, **2020**, 252, 433-440	9.4	5
129	Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1. *Acta Neuropathologica*, **2021**, 142, 179-189	14.3	5
128	Clinicopathologic and molecular analysis of embryonal rhabdomyosarcoma of the genitourinary tract: evidence for a distinct DICER1-associated subgroup. *Modern Pathology*, **2021**, 34, 1558-1569	9.8	5
127	Downregulation of miR-326 and its host gene □-arrestin1 induces pro-survival activity of E2F1 and promotes medulloblastoma growth. *Molecular Oncology*, **2021**, 15, 523-542	7.9	5
126	Rapid MALDI-MS Assays for Drug Quantification in Biological Matrices: Lessons Learned, New Developments, and Future Perspectives. *Molecules*, **2021**, 26,	4.8	5

125	Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p. *Acta Neuropathologica*, **2018**, 136, 975-978	14.3	5
124	Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. *Acta Neuropathologica*, **2021**, 142, 827-839	14.3	5
123	A Summary of the Inaugural WHO Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular Era.. *Cancer Discovery*, **2021**,	24.4	5
122	Systematic target actionability reviews of preclinical proof-of-concept papers to match targeted drugs to paediatric cancers. *European Journal of Cancer*, **2020**, 130, 168-181	7.5	4
121	Pilocytic astrocytoma demethylation and transcriptional landscapes link bZIP transcription factors to immune response. *Neuro-Oncology*, **2020**, 22, 1327-1338	1	4
120	Molecular Diagnostics in Pediatric Brain Tumors: Impact on Diagnosis and Clinical Decision-Making - A Selected Case Series. *Klinische Padiatrie*, **2018**, 230, 305-313	0.9	4
119	BI-30 * CHARACTERIZATION OF L1CAM AS A CLINICAL MARKER FOR THE C11orf95-RELA FUSION IN SUPRATENTORIAL EPENDYMOMAS. *Neuro-Oncology*, **2014**, 16, v30-v30	1	4
118	GE-23 * ENHANCER HIJACKING ACTIVATES GFI1 FAMILY ONCOGENES IN MEDULLOBLASTOMA. *Neuro-Oncology*, **2014**, 16, v101-v101	1	4
117	Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation Neuro Master Match (N□M□).. *Journal of Clinical Oncology*, **2016**, 34, TPS2084-TPS2084	2.2	4
116	Dissecting telomere maintenance mechanisms in pediatric glioblastoma		4
115	Single cell derived mRNA signals across human kidney tumors		4
114	Genome-wide analysis of acute leukemia and clonally related histiocytic sarcoma in a series of three pediatric patients. *Pediatric Blood and Cancer*, **2020**, 67, e28074	3	4
113	Single cell derived mRNA signals across human kidney tumors. *Nature Communications*, **2021**, 12, 3896	17.4	4
112	FOXR2 Stabilizes MYCN Protein and Identifies Non--Amplified Neuroblastoma Patients With Unfavorable Outcome. *Journal of Clinical Oncology*, **2021**, 39, 3217-3228	2.2	4
111	High-Resolution Cartography of the Transcriptome and Methylome Landscapes of Diffuse Gliomas. *Cancers*, **2021**, 13,	6.6	4
110	Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signature. *Modern Pathology*, **2021**, 34, 2122-2129	9.8	4
109	Maturation Block in Childhood Cancer. *Cancer Discovery*, **2021**, 11, 542-544	24.4	4
108	Identification of CD24 as a marker of Patched1 deleted medulloblastoma-initiating neural progenitor cells. *PLoS ONE*, **2019**, 14, e0210665	3.7	3

107	Medulloepithelioma with peculiar clinical presentation, stem cell phenotype and aberrant DNA-methylation profile. *CNS Oncology*, **2015**, 4, 203-12	4	3
106	An optimized workflow to improve reliability of detection of KIAA1549:BRAF fusions from RNA sequencing data. *Acta Neuropathologica*, **2020**, 140, 237-239	14.3	3
105	INFORM2 exploratory multinational phase I/II combination study of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies: INFORM2 NivEnt.. *Journal of Clinical Oncology*, **2019**, 37, TPS10065-TPS10065	2.2	3
104	EZHIP: a new piece of the puzzle towards understanding pediatric posterior fossa ependymoma. *Acta Neuropathologica*, **2021**, 143, 1	14.3	3
103	Integrative gene network and functional analyses identify a prognostically relevant key regulator of metastasis in Ewing sarcoma.. *Molecular Cancer*, **2022**, 21, 1	42.1	3
102	Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas. *Science Translational Medicine*, **2021**, 13, eabc0497	17.5	3
101	Notch Signaling between Cerebellar Granule Cell Progenitors. *ENeuro*, **2021**, 8,	3.9	3
100	International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer. *Molecular Cancer Therapeutics*, **2021**, 20, 1462-1468	6.1	3
99	From Sampling to Sequencing: A Liquid Biopsy Pre-Analytic Workflow to Maximize Multi-Layer Genomic Information from a Single Tube. *Cancers*, **2021**, 13,	6.6	3
98	Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. *Neuro-Oncology*, **2021**, 23, 1597-1611	1	3
97	Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse. *Neuro-Oncology*, **2021**,	1	3
96	Integrated molecular analysis of adult sonic hedgehog (SHH)-activated medulloblastomas reveals two clinically relevant tumor subsets with VEGFA as potent prognostic indicator. *Neuro-Oncology*, **2021**, 23, 1576-1585	1	3
95	Radiation-induced gliomas represent H3-/IDH-wild type pediatric gliomas with recurrent PDGFRA amplification and loss of CDKN2A/B. *Nature Communications*, **2021**, 12, 5530	17.4	3
94	LGG-02. A PHASE II PROSPECTIVE TRIAL OF SELUMETINIB IN CHILDREN WITH RECURRENT/PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMA (PLGG) WITH A FOCUS UPON OPTIC PATHWAY/HYPOTHALAMIC TUMORS AND VISUAL ACUITY OUTCOMES: A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY, PBTC-029B. *Neuro-Oncology*, **2019**, 21, ii30-ii30	1	2
93	Molecular progression of SHH-activated medulloblastomas. *Acta Neuropathologica*, **2019**, 138, 327-330	14.3	2
92	Two molecularly distinct atypical teratoid/rhabdoid tumors (or tumor components) occurring in an infant with rhabdoid tumor predisposition syndrome 1. *Acta Neuropathologica*, **2019**, 137, 847-850	14.3	2
91	Paired box gene 8 (PAX8) expression is associated with sonic hedgehog (SHH)/wingless int (WNT) subtypes, desmoplastic histology and patient survival in human medulloblastomas. *Neuropathology and Applied Neurobiology*, **2015**, 41, 165-79	5.2	2
90	Gene-Tailored Treatments for Brain Disorders: Challenges and Opportunities. *Public Health Genomics*, **2016**, 19, 170-7	1.9	2

89	Medulloblastoma: a potpourri of distinct entities. *Acta Neuropathologica*, **2012**, 123, 463-4	14.3	2
88	Reply to J.C. Lindsey et al. *Journal of Clinical Oncology*, **2011**, 29, e348-e349	2.2	2
87	Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival.. *Acta Neuropathologica Communications*, **2022**, 10, 5	7.3	2
86	Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies. *Journal of Neuro-Oncology*, **2021**, 155, 193-202	4.8	2
85	Primary central nervous system sarcoma with DICER1 mutation-treatment results of a novel molecular entity in pediatric Peruvian patients. *Cancer*, **2021**,	6.4	2
84	Spatial Dissection of Invasive Front from Tumor Mass Enables Discovery of Novel microRNA Drivers of Glioblastoma Invasion. *Advanced Science*, **2021**, 8, e2101923	13.6	2
83	Establishment of a simplified preparation method for single-nucleus RNA-sequencing and its application to long-term frozen tumor tissues		2
82	Molecular tumor classification using DNA methylome analysis. *Human Molecular Genetics*, **2020**, 29, R205-R213	5.8	2
81	The age of adult pilocytic astrocytoma cells. *Oncogene*, **2021**, 40, 2830-2841	9.2	2
80	Integrated phospho-proteogenomic and single-cell transcriptomic analysis of meningiomas establishes robust subtyping and reveals subtype-specific immune invasion		2
79	Development of Randomized Trials in Adults with Medulloblastoma-The Example of EORTC 1634-BTG/NOA-23. *Cancers*, **2021**, 13,	6.6	2
78	Desmoplastic/nodular medulloblastomas (DNMB) and medulloblastomas with extensive nodularity (MBEN) disclose similar epigenetic signatures but different transcriptional profiles. *Acta Neuropathologica*, **2019**, 137, 1003-1015	14.3	2
77	An extracellular vesicle-related gene expression signature identifies high-risk patients in medulloblastoma. *Neuro-Oncology*, **2021**, 23, 586-598	1	2
76	Accurate calling of KIAA1549-BRAF fusions from DNA of human brain tumours using methylation array-based copy number and gene panel sequencing data. *Neuropathology and Applied Neurobiology*, **2021**, 47, 406-414	5.2	2
75	Molecular analysis of pediatric CNS-PNET revealed nosologic heterogeneity and potent diagnostic markers for CNS neuroblastoma with FOXR2-activation. *Acta Neuropathologica Communications*, **2021**, 9, 20	7.3	2
74	Subgroup and subtype-specific outcomes in adult medulloblastoma. *Acta Neuropathologica*, **2021**, 142, 859-871	14.3	2
73	MRI Radiogenomics of Pediatric Medulloblastoma: A Multicenter Study.. *Radiology*, **2022**, 212137	20.5	2
72	GENE-08. THE MNP 2.0 STUDY: PROSPECTIVE INTEGRATION OF DNA METHYLATION PROFILING IN CNS TUMOR DIAGNOSTICS. *Neuro-Oncology*, **2019**, 21, ii82-ii82	1	1

71	Next-generation molecular diagnostics. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2016**, 134, 121-30	3	1
70	MEDU-01. HDACi AND PLK1i ACT SYNERGISTICALLY IN MYC-AMPLIFIED MEDULLOBLASTOMA. *Neuro-Oncology*, **2019**, 21, ii103-ii103	1	1
69	Probing Medulloblastoma Initiation at the Single-Cell Level. *Trends in Cancer*, **2019**, 5, 759-761	12.5	1
68	Revealing the role of SGK1 in the dynamics of medulloblastoma using a mathematical model. *Journal of Theoretical Biology*, **2014**, 354, 105-12	2.3	1
67	ICGC PedBrain - dissecting the genomic complexity underlying medulloblastoma using whole-genome sequencing. *BMC Proceedings*, **2012**, 6,	2.3	1
66	Important Requirements for the Selection of Internal Standards during the Development of Desorption/Ionization Assays for Drug Quantification in Biological Matrices-A Practical Example.. *Molecules*, **2022**, 27,	4.8	1
65	Clinical and molecular subgroups of ependymoma in adulthood: An analysis of the German Glioma Network.. *Journal of Clinical Oncology*, **2017**, 35, 2038-2038	2.2	1
64	Genetic and epigenetic characterization of posterior pituitary tumors. *Acta Neuropathologica*, **2021**, 142, 1025-1043	14.3	1
63	ETMR-03. THE ROLE OF FOXR2 IN PEDIATRIC BRAIN CANCER. *Neuro-Oncology*, **2020**, 22, iii323-iii323	1	1
62	Cancer predisposition in pediatric neuro-oncology-practical approaches and ethical considerations. *Neuro-Oncology Practice*, **2021**, 8, 526-538	2.2	1
61	Carbon ion radiotherapy eradicates medulloblastomas with chromothripsis in an orthotopic Li-Fraumeni patient-derived mouse model. *Neuro-Oncology*, **2021**, 23, 2028-2041	1	1
60	Systematic multi-omics cell line profiling uncovers principles of Ewing sarcoma fusion oncogene-mediated gene regulation		1
59	Bioanalysis of selinexor in mouse plasma micro-samples utilizing UPLC-MS/MS. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2021**, 1176, 122781	3.2	1
58	CRISPR-mediated Loss of Function Analysis in Cerebellar Granule Cells Using In Utero Electroporation-based Gene Transfer. *Journal of Visualized Experiments*, **2018**,	1.6	1
57	GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types. *Acta Neuropathologica*, **2021**, 142, 1065-1069	14.3	1
56	Molecular profiling of pediatric meningiomas shows tumor characteristics distinct from adult meningiomas. *Acta Neuropathologica*, **2021**, 142, 873-886	14.3	1
55	Analytical Performance Evaluation of New DESI Enhancements for Targeted Drug Quantification in Tissue Sections. *Pharmaceuticals*, **2022**, 15, 694	5.2	1
54	Target actionability review to evaluate CDK4/6 as a therapeutic target in paediatric solid and brain tumours. *European Journal of Cancer*, **2022**, 170, 196-208	7.5	1

53	EPEN-06. YAP1 SUBGROUP SUPRATENTORIAL EPENDYMOMA REQUIRES TEAD AND NUCLEAR FACTOR I-MEDIATED TRANSCRIPTIONAL PROGRAMS FOR TUMORIGENESIS. *Neuro-Oncology*, **2019**, 21, ii78-ii78	1	0
52	GENE-12. ANAPLASTIC NEUROEPITHELIAL TUMOR WITH CONDENSED NUCLEI (ANTCON): A NOVEL BRAIN TUMOR ENTITY WITH RECURRENT NTRK FUSION. *Neuro-Oncology*, **2019**, 21, ii83-ii83	1	0
51	Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignancies.. *European Journal of Cancer*, **2021**, 162, 107-117	7.5	0
50	A systematic analysis of genetic interactions and their underlying biology in childhood cancer. *Communications Biology*, **2021**, 4, 1139	6.7	0
49	EPEN-39. CLINICAL STRATIFIED TREATMENT OF LOCALIZED PEDIATRIC INTRACRANIAL EPENDYMOMA WITH COMBINED LOCAL IRRADIATION AND CHEMOTHERAPY WITHIN THE PROSPECTIVE, MULTICENTER E-HIT TRIAL THE MOLECULAR SUBGROUP MATTERS. *Neuro-Oncology*, **2020**, 22, iii315-iii316	1	0
48	Thrombospondin-1 mimetics are promising novel therapeutics for MYC-associated medulloblastoma. *Neuro-Oncology Advances*, **2021**, 3, vdab002	0.9	0
47	Predictive modeling of resistance to SMO inhibition in a patient-derived orthotopic xenograft model of SHH medulloblastoma.. *Neuro-Oncology Advances*, **2022**, 4, vdac026	0.9	0
46	Rapid-CNS: rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof-of-concept study.. *Acta Neuropathologica*, **2022**, 1	14.3	0
45	The genomic landscape of pediatric renal cell carcinomas.. *IScience*, **2022**, 25, 104167	6.1	0
44	Reply to 'Assembling the brain trust: the multidisciplinary imperative in neuro-oncology'. *Nature Reviews Clinical Oncology*, **2019**, 16, 522-523	19.4	
43	Ependymoma. *Molecular Pathology Library*, **2015**, 67-75		
42	Medulloblastoma and CNS Primitive Neuroectodermal Tumors. *Molecular Pathology Library*, **2015**, 121-142		
41	Guanine nucleotide-binding protein subunit hypofunction in children with short stature and disproportionate shortening of the 4th and 5th metacarpals. *Hormone Research in Paediatrics*, **2014**, 81, 196-203	3.3	
40	The Early Treatment Response of the Clinically Challenging Group of Childhood T-ALL without NOTCH1 Mutations Is Signified by a Specific mRNA Gene Profile.. *Blood*, **2007**, 110, 2789-2789	2.2	
39	Secretion of Angiogenic Proteins by Human Multipotent Mesenchymal Stromal Cells (MSC) under Hypoxic Culture Conditions and Clinical Application of MSC in Steroid Induced Osteonecrosis in Children.. *Blood*, **2007**, 110, 3689-3689	2.2	
38	Präzisionsonkologie und Phase-I/II-Netzwerke in der Kinderkrebsmedizin **2021**, 36, 485	0.2	
37	High-Resolution Genomic Profiling (array-CGH) of Childhood T-ALL Identifies Deletions at 6q15-16.1 as a Predictive Marker for Early Treatment Response.. *Blood*, **2008**, 112, 1484-1484	2.2	
36	Progressively Metastasizing Ependymoma: Genomic Aberrations **2012**, 297-306		

35	LGG-04. MULTIOMIC ANALYSIS OF MAPK PATHWAY ACTIVITY IN PEDIATRIC PILOCYTIC ASTROCYTOMA. *Neuro-Oncology*, **2021**, 23, i31-i32	1
34	TMOD-03. A NOVEL MB GR3 TRANSGENIC MOUSE MODEL IS GENERATED BY MYCN AND P53 DEFECTS IN VENTRICULAR ZONE PROGENITORS.. *Neuro-Oncology*, **2021**, 23, i36-i36	1
33	ABCB1 inhibition provides a novel therapeutic target to block TWIST1-induced migration in medulloblastoma. *Neuro-Oncology Advances*, **2021**, 3, vdab030	0.9
32	Alterations in Pediatric High-Risk Malignancies Identified Through European Clinical Sequencing Programs Constitute Promising Drug Targets.. *JCO Precision Oncology*, **2021**, 5, 450-454	3.6
31	Modern Principles of CNS Tumor Classification **2018**, 117-129	
30	A Mouse Ependymoma Model Provides Molecular Insights into Tumor Formation. *Cell Reports*, **2018**, 23, 3699-3700	10.6
29	Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies.. *Journal of Neuro-Oncology*, **2022**, 157, 37	4.8
28	MODL-02. A novelCre-conditionalcMYC-driven MB Group 3 transgenic mouse model shows traceable leptomeningeal dissemination.. *Neuro-Oncology*, **2022**, 24, i168-i168	1
27	RARE-12. Pineoblastoma of children and young adults in a national population: An analysis of the HIT-MED study cohort. *Neuro-Oncology*, **2022**, 24, i11-i12	1
26	HGG-50. Specific sensitivity of pediatric high-grade glioma with ATRX inactivation to PARP inhibitor combinations. *Neuro-Oncology*, **2022**, 24, i73-i73	1
25	PATH-08. DNA methylation profiling improves routine diagnostics of paediatric CNS tumours: a prospective population-based study. *Neuro-Oncology*, **2022**, 24, i159-i160	1
24	HGG-27. Understanding the role of PLAG family transcription factors in cortex development and tumorigenesis. *Neuro-Oncology*, **2022**, 24, i66-i66	1
23	MODL-04. Drug screening in Disorders with Abnormal DNA Damage Response/Repair (DADDR) andin vivo validation. *Neuro-Oncology*, **2022**, 24, i168-i169	1
22	MEDB-60. Medulloblastoma with extensive nodularity mimics cerebellar development and differentiates along the granular precursor lineage. *Neuro-Oncology*, **2022**, 24, i120-i120	1
21	MEDB-38. Significance of CSF cytology and neurologic deterioration in relapsed medulloblastomas in the German HIT-REZ-97/-2005 Studies and the HIT-REZ-Register. *Neuro-Oncology*, **2022**, 24, i113-i114	1
20	MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. *Neuro-Oncology*, **2022**, 24, i107-i107	1
19	OTHR-32. The Pediatric Targeted Therapy 2.0 registry: robust molecular diagnostics for precision oncology. *Neuro-Oncology*, **2022**, 24, i154-i154	1
18	PATH-13. Methylation analysis in the diagnosis of pediatric CNS tumors; a single center experience. *Neuro-Oncology*, **2022**, 24, i161-i161	1

17	MEDB-41. Identifying a subgroup of patients with early childhood sonic hedgehog-activated medulloblastoma with unfavorable prognosis after treatment with radiation-sparing regimens including intraventricular methotrexate. *Neuro-Oncology*, **2022**, 24, i114-i115	1
16	PATH-03. Clinically Tractable Outcome Prediction of Group 3/4 Medulloblastoma Based on TPD52 Immunohistochemistry: a Multicohort Study. *Neuro-Oncology*, **2022**, 24, i158-i158	1
15	HGG-11. Clinical characteristics and clinical evolution of a large cohort of pediatric patients with primary central nervous system (CNS) tumors and tropomyosin receptor kinase (TRK) fusion.. *Neuro-Oncology*, **2022**, 24, i61-i62	1
14	MEDB-36. Clinical and molecular heterogeneity withinMYC andMYCN amplified medulloblastoma. *Neuro-Oncology*, **2022**, 24, i113-i113	1
13	LGG-14. LOGGIC (Low Grade Glioma in Children) Core BioClinical Data Bank: Establishment and added clinical value of an international molecular diagnostic registry for pediatric low-grade glioma patients. *Neuro-Oncology*, **2022**, 24, i90-i90	1
12	MEDB-15. Dynamic chromatin alteration induces oncogenic hijacking by essential transcriptional factors during SHH medulloblastoma tumorigenesis. *Neuro-Oncology*, **2022**, 24, i107-i108	1
11	MODL-07. DNA methylation-based biobank of murine models for pediatric tumors. *Neuro-Oncology*, **2022**, 24, i169-i170	1
10	EPEN-28. Oncogenic dependency of pediatric ependymomas on extracellular vesicle pathways. *Neuro-Oncology*, **2022**, 24, i45-i45	1
9	IMMU-04. Transcriptional analysis reveals distinct microenvironmental subgroups across pediatric nervous system tumors. *Neuro-Oncology*, **2022**, 24, i81-i81	1
8	HGG-61.Landscape of cancer predisposition in pediatric high-grade glioma. *Neuro-Oncology*, **2022**, 24, i76-i76	1
7	EPEN-09. Multi-omics characterization of the blood-brain barrier in molecular groups of ependymoma. *Neuro-Oncology*, **2022**, 24, i40-i40	1
6	DIPG-19. FOXR2 is an oncogenic driver across pediatric and adult cancers. *Neuro-Oncology*, **2022**, 24, i21-i22	1
5	PATH-11. Detection of genetic and epigenetic alterations in Liquid Biopsies from pediatric brain tumor patients. *Neuro-Oncology*, **2022**, 24, i160-i161	1
4	MEDB-04. Young children with metastatic medulloblastoma: frequent requirement for radiotherapy in children with non-WNT/non-SHH medulloblastoma despite highly intensified chemotherapy Results of the MET-HIT2000-BIS4 trial. *Neuro-Oncology*, **2022**, 24, i104-i104	1
3	RARE-15. Astroblastoma, MN1 altered comprises two molecularly and clinically distinct subgroups defined by the fusion partners BEND2 and CXXC5. *Neuro-Oncology*, **2022**, 24, i12-i13	1
2	THER-01. Precision brain tumor therapy by AAV-mediated oncogene editing. *Neuro-Oncology*, **2022**, 24, i185-i186	1
1	MODL-01. Targeting replication stress in pediatric brain tumors. *Neuro-Oncology*, **2022**, 24, i168-i168	1